Interestingly, the gene probes targeting FGF17, PRKCG, SSTR1, and SCTR predicted potential targeted agents for renal cancer metastasis and adjuvant immunotherapy, including 5224221, calmidazolium, and sulfasalazine. Here, PRKCG is linked to renal carcinoma.